Padsevonil (UCB0942) | UCB
UCB's Global Corporate Website

Padsevonil (UCB0942)

Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available)
Epilepsy Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy. Phase 2 EP0069
Completed
NCT02495844
2014-003330-12
LINK
LINK
Van Paesschen W. [abstract 1.289] available on Annual Meeting Abstract Database www.aesnet.org
Epilepsy An open-label, multicenter, extension study to evaluate the long-term safety, tolerability, and efficacy of UCB0942 when used as adjunctive therapy for partial-onset seizures in adult subjects with highly drug-resistant focal epilepsy Phase 2 Phase 2 EP0073
Terminated
NCT02625090
2015-001268-20
LINK
LINK
Epilepsy The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy Phase 2 EP0091
Completed
NCT03373383
2017-003200-48
LINK
LINK
Werhahn K.J., et al [abstract 130] 74th Annual Meeting of the American Epilepsy Society (AES), December 04-08, 2020; Online www.aesnet.org
Epilepsy A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy (DUET) Phase 3 EP0092
Completed
NCT03739840
2018-002303-33
LINK
LINK
Epilepsy Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy Phase 2/3 EP0093
Terminated
NCT03370120
2017-003241-26
LINK
LINK